Information Provided By: 
Fly News Breaks for April 16, 2019
ORGO
Apr 16, 2019 | 16:14 EDT
Oppenheimer analyst Steven Lichtman initiated coverage of Organogenesis with an Outperform rating and $11 price target. The company has a "diverse product set at different levels of complexity and price points that address a wide spectrum of wounds and musculoskeletal injuries," Lichtman tells investors in a research note. The analyst sees Organogenesis' markets as growing more than high-single digits and not highly penetrated. He calls the company as a "well-positioned regenerative medicine story."
News For ORGO From the Last 2 Days
There are no results for your query ORGO
